SCHEMBL560371

SCHEMBL560371

Cc1ccc2nc(-c3nc(C(=O)NCc4ccco4)cnc3N)[nH]c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 6/20 0.54
HTT P42858 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
SMN1; SMN2 Q16637 6/20 0.51
ALDH1A1 P00352 6/20 0.51
HSD17B10 Q99714 5/20 0.51
USP2 O75604 4/20 0.51
HPGD P15428 4/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
ATR Q13535 4/20 0.48
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
MAPT P10636 5/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
TP53 P04637 3/20 0.47
LMNA P02545 2/20 0.47
KDM4E B2RXH2 5/20 0.47
TDP1 Q9NUW8 4/20 0.47
CASP3 P42574 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560651 0.85 ATR (0.53) HTTSMN1; SMN2USP2ATRRAB9A
SCHEMBL560367 0.82 POLB (0.51) POLBHTTSMN1; SMN2ALDH1A1HPGD
SCHEMBL560220 0.82 ATR (0.53) POLBSMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL10166538 0.82 ATR (0.57) POLBALDH1A1HPGDATRMAPT
SCHEMBL559632 0.82 ATR (0.49) POLBSMN1; SMN2ATRMAPTTP53
SCHEMBL560074 0.82 ATR (0.52) POLBSMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL560124 0.82 ATR (0.52) POLBSMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL560801 0.81 ATR (0.54) POLBALDH1A1HSD17B10HPGDATR
SCHEMBL559812 0.81 ATR (0.51) POLBSMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL560594 0.81 ATR (0.55) POLBALDH1A1HPGDATRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 POLB 770/4885HTT 2225/4885NPSR1 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.